Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 71

Results For "RNA"

2772 News Found

Health Minister Nadda to inaugurate India MedTech Expo 2025
News | September 03, 2025

Health Minister Nadda to inaugurate India MedTech Expo 2025

The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives


iPHEX 2025: Global regulatory conclaves to highlight India’s role in shaping global health
News | September 03, 2025

iPHEX 2025: Global regulatory conclaves to highlight India’s role in shaping global health

This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings


Metal-free catalysis is transforming future of sustainable pharmaceutical innovation
Opinion | September 03, 2025

Metal-free catalysis is transforming future of sustainable pharmaceutical innovation

It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals


Fortis takes over 200-bed Greater Noida hospital on long term lease
Healthcare | September 02, 2025

Fortis takes over 200-bed Greater Noida hospital on long term lease

Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network


Medanta launches 550-bed super specialty hospital in Noida
Healthcare | September 02, 2025

Medanta launches 550-bed super specialty hospital in Noida

The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres


Glenmark Pharmaceuticals USA to launch Eribulin Mesylate injection
News | September 02, 2025

Glenmark Pharmaceuticals USA to launch Eribulin Mesylate injection

Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai


Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran
News | August 31, 2025

Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran

Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives


FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19
Drug Approval | August 31, 2025

FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19

Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season